Frontiers in Endocrinology (Mar 2019)
Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status
- Yu-Tang Chin,
- Yu-Tang Chin,
- Zong-Rong He,
- Zong-Rong He,
- Chi-Long Chen,
- Hsiao-Ching Chu,
- Yih Ho,
- Yih Ho,
- Po-Yu Su,
- Yu-Chen S. H. Yang,
- Kuan Wang,
- Kuan Wang,
- Ya-Jung Shih,
- Ya-Jung Shih,
- Yi-Ru Chen,
- Yi-Ru Chen,
- Jens Z. Pedersen,
- Sandra Incerpi,
- André Wendindondé Nana,
- Heng-Yuan Tang,
- Hung-Yun Lin,
- Hung-Yun Lin,
- Hung-Yun Lin,
- Hung-Yun Lin,
- Hung-Yun Lin,
- Shaker A. Mousa,
- Paul J. Davis,
- Paul J. Davis,
- Jacqueline Whang-Peng,
- Jacqueline Whang-Peng,
- Jacqueline Whang-Peng
Affiliations
- Yu-Tang Chin
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Yu-Tang Chin
- Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
- Zong-Rong He
- Department of Pediatrics, E-Da Hospital, Kaohsiung, Taiwan
- Zong-Rong He
- School of Medicine, I-Shou University, Kaohsiung, Taiwan
- Chi-Long Chen
- School of Medicine, Taipei Medical University, Taipei, Taiwan
- Hsiao-Ching Chu
- Division of Medical Imaging, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan
- Yih Ho
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Yih Ho
- School of Pharmacy, Taipei Medical University, Taipei, Taiwan
- Po-Yu Su
- Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
- Yu-Chen S. H. Yang
- Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan
- Kuan Wang
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Kuan Wang
- Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
- Ya-Jung Shih
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Ya-Jung Shih
- Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
- Yi-Ru Chen
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Yi-Ru Chen
- Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan
- Jens Z. Pedersen
- 0Department of Biology, University of Rome Tor Vergata, Rome, Italy
- Sandra Incerpi
- 1Department of Sciences, Roma Tre University, Rome, Italy
- André Wendindondé Nana
- 2Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
- Heng-Yuan Tang
- 3Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, United States
- Hung-Yun Lin
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Hung-Yun Lin
- 2Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
- Hung-Yun Lin
- 3Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, United States
- Hung-Yun Lin
- 4TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan
- Hung-Yun Lin
- 5Traditional Herbal Medicine Research Center of Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan
- Shaker A. Mousa
- 3Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, United States
- Paul J. Davis
- 3Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, United States
- Paul J. Davis
- 6Department of Medicine, Albany Medical College, Albany, NY, United States
- Jacqueline Whang-Peng
- Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
- Jacqueline Whang-Peng
- Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
- Jacqueline Whang-Peng
- 2Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
- DOI
- https://doi.org/10.3389/fendo.2019.00130
- Journal volume & issue
-
Vol. 10
Abstract
Colorectal cancer is a serious medical problem in Taiwan. New, effective therapeutic approaches are needed. The selection of promising anticancer drugs and the transition from pre-clinical investigations to clinical trials are often challenging. The deaminated thyroid hormone analog (tetraiodothyroacetic acid, tetrac) and its nanoparticulate analog (NDAT) have been shown to have anti-proliferative activity in vitro and in xenograft model of different neoplasms, including colorectal cancers. However, mechanisms involved in tetrac- and NDAT-induced anti-proliferation in colorectal cancers are incompletely understood. We have investigated possible mechanisms of tetrac and NDAT action in colorectal cancer cells, using a perfusion bellows cell culture system that allows efficient, large-scale screening for mechanisms of drug actions on tumor cells. Although integrin αvβ3 in K-RAS wild type colorectal cancer HT-29 cells was far less than that in K-RAS mutant HCT116 cells, HT-29 was more sensitive to both tetrac and NDAT. Results also indicate that both tetrac and NDAT bind to tumor cell surface integrin αvβ3, and the agents may have different mechanisms of anti-proliferation in colorectal cancer cells. K-RAS status appears to play an important role in drug resistance that may be encountered in treatment with this drug combination.
Keywords
